Menu
← Oncology Approval Tracker
FDA DECISION ·
Lunsumio
mosunetuzumab-axgb · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma following at least two lines of systemic therapy.
LAMPGEN ANALYSIS
Why it matters
The original accelerated approval adds a CD20-directed bispecific in later-line follicular lymphoma.
What research teams should watch
Verify prior lines and coordinate step-up dosing, monitoring and escalation for cytokine release syndrome.
PRIMARY RECORDS